ClinicalTrials.gg
RecruitingNCT06298474Updated Sep 15, 2026

The BRAIN App (Phase 2 SBIR)

An interventional study of The BRAIN App in Dementia, Alzheimer Disease and Vascular Dementia, sponsored by Hopeful Aging. Recruiting at 1 site in United States. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by Hopeful Aging · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 1,051 studies in Dementia with a site in United States — 211 open to participants now, 276 under way, 15 of them phase 3. Dementia · United States.

Planned enrollment
359th of 846
120 · median 93
Started
2025
with 60 others
No phase
562 of 1,051
118 open now
Primary completion
2026-11
later than 74 of 275 live
Registered
877th of 1,051
by date

Among the 1,051 studies in Dementia with a site in United States, this one is the 359th largest by planned enrollment of the 846 interventional ones that give a count, is one of 61 that started in 2025, is one of 562 with no phase, reaches primary completion later than 74 of the 275 other live ones, and was the 877th registered.

Dementia

2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.

Browse Dementia studies →

Open to participants now

211 of the 1,051 studies in Dementia with a site in United States are open now. Recruiting first, the newest first:

206 more — sign in →

All 211 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,051 studies in Dementia with a site in United States, or all of them as a file.
02

Study summary

There are currently 6.7 million Americans living with dementia and, without significant breakthroughs, this figure will double to 12.7 million by 2050. There are about 46,000 long-term care (LTC) facilities in the U.S. More than half of LTC residents have some form of dementia (Alzheimer's Association, 2018). Responsive behaviors and dysfunction of the dementia care triad-i.e., the PLWD, professional Care Partner (CP), and Family Member (FM)-are inexorably linked. The emergence of responsive behaviors can lead to disruption of the triad's function. Thus, it is imperative to maintain positive relationships and a high quality of life (QoL) within the triad to reduce BPSD. Cognitive Stimulation Therapy (CST) has demonstrated improvements in QoL and relationships for PLWD. CST is a psychosocial intervention that promotes communication and engagement in PLWD via a structured program of meaningful and enjoyable theme. While clinical trials have shown improvement in cognition and QoL, the potential large-scale impact of CST has been hampered by low adherence, with less than 40% completing trials. One likely reason for the low adherence to CST is the reliance on generic and non-digital tools (e.g., paper-based agendas, tools, DVDs, and board games) in facilitating the intervention. That is, even though CST aims to be personalized, the specific interventions used in the field tend to be generic and not tailored to each PLWD's specific interests. The use of digital technology to implement CST would offer considerable advantages to expand and personalize the range of stimulation content and provide a means for monitoring responses, optimizing protocols, and promoting adherence.

The proposed Phase II study will involve the continued development and evaluation of a multi-faceted software platform called "Building Relationships using Artificial Intelligence and Nostalgia" or BRAIN. The BRAIN Platform will be the first-ever Artificial Intelligence (AI) powered CST digital therapy platform for PLWD. The platform, which has been shown to be effective in an initial Phase I clinical trial, has three main goals: to improve the quality of life of PLWD, to reduce BPSD in PLWD, and to foster positive relationships between members of the care triad. The proposed Phase II project has the following Specific Aims: 1. Create an improved Beta version of the BRAIN Platform's eight components: (1) the Admin Management Dashboard, (2) the Annotation Dashboard, (3) the Log Viewer, (4) the Content Management System (CMS), (5) the Private CMS, (6) the Control App, (7) the Home App, and (8) the Training Dashboard. 2. Fine-tune the different classes of AI algorithms-i.e., behavioral analytics, personalized content recommendation, and personalized program generation-in the BRAIN app such that they can (a) recognize and track 12 distinct behaviors and indicators of PLWD, (b) use these behavioral traits as a basis for automatically rating the relative success of each activity, and (c) automatically recommend personalized activities that are likely to be successful for individual PLWD. 3. Conduct a Cluster Randomized Trial (CRT) of the BRAIN App to examine the app's impact on engagement/affect, quality of life, and responsive behaviors. 4. Examine satisfaction and ease of use of the app for PLWD, LTC staff, and FMs.

Read the detailed description

Sample Sample PLWD, The primary sample will consist of 120 PLWD-i.e., at each of the 8 LTC facilities, 15 PLWD will participate in the study (8 sites x 15 PLWD = 120 PLWD). Half of the PLWD (n=60) will be in the Experimental Group and the other half (n=60) will be in the Control Group. PLWD will be split equally between NHs and ALFs, so sample sizes will be as follows for each site type/condition: Experimental NH, n=30; Experimental ALF, n=30; Control NH, n=30; Control ALF, n=30. Family Members For each PLWD living at an Experimental Site, one family member will participate in the study. As such, 60 Family Members will participate in the study. Family Members will facilitate the BRAIN intervention twice per month and provide feedback related to satisfaction and ease of use. Staff Members At each Experimental Site, 6 staff members will participate, including 1 administrator/executive director, 1 activity staff member, and 3 CPs. Since there are four Experimental Sites, 24 staff members will participate. Staff members will take the BRAIN Training Modules, use the BRAIN Platform at least twice, and provide feedback related to satisfaction and ease of use. Diversity: As was true in Phase I, we are committed to testing the app with a diverse sample.

Study Design The study will utilize a quasi-experimental pre-post design-i.e., baseline vs. treatment / post-treatment.

Inclusion/Exclusion Criteria Inclusion Criteria: PLWD, 65+ years old, dementia diagnosis (any type), and able to speak conversational English; Family/Staff Members, 18+ years old and able to speak English. (Activity content/questionnaires will be in English).

Exclusion Criteria PLWD, completely unable to communicate verbally, serious visual or hearing impairments, and/or signs of rapid decline over the last three months (based upon staff report); Family/Staff Members, none.

Analyses Primary Outcomes: Engagement/affect, quality of life, and responsive behaviors/BPSD.

Secondary Outcomes: Cognition, depression, and quality of the relationship between the family member and PLWD.

The BRAIN Platform will be considered successful if the following results are found:

  1. PLWD in the Experimental Group experience significantly greater increases in positive engagement/affect and/or significantly greater decreases in negative engagement (measured by MPES and EPWDS) from baseline to treatment, than the Control Group. A two-way mixed design ANOVA will be used to analyze MPES and EPWDS data, with a between-subjects factor of GROUP (Control vs. Experimental) and within-subjects factor of TIME (baseline vs. treatment). We anticipate detecting a Group x Time interaction effect for MPES and EPWDS data, with Experimental Group participants exhibiting significantly greater increases in positive forms of engagement/affect at treatment, and significantly greater decreases in negative forms of engagement/affect, as compared to Control Group participants. With a sample of 120 and using means and standard deviations for constructive engagement (an MPES item) from Phase 1, we will have a power of 99% to detect effects (alpha=0.05; one-tailed test).
  2. PLWD in the Experimental Group experience one or more of the following: (a) significantly greater increases in QoL than those in the control group, (b) significantly greater decreases in Responsive Behaviors, (c) significantly greater decreases in cognition, (d) significantly greater decreases in depression, and/or (e) significantly improved relationships between family members and PLWD (based upon the QCRP). A two-way mixed design ANOVA will also be used, with a between-subjects factor of GROUP and within-subjects factor of TIME. We anticipate detecting a Group x Time interaction effect for at least one of these domains (QoL, responsive behaviors, cognition, depression, and/or relationships). With a sample of 120, and using DEMQOL means and standard deviations from Phase 1, we will have a power of 90% to detect effects (alpha=0.05; one-tailed test).
  3. PLWD and staff report high satisfaction with the app, defined as 85% being satisfied with the app. This will be determined by calculating mean % of times participants answered "yes" to satisfaction questions for all participant types.
  4. Staff and Family members demonstrate knowledge transfer after taking the BRAIN Training Modules. This will be determined by conducting a paired sample t-test (pre-training quizzes vs. post-training quizzes).

B. Study Procedures, Materials, and Potential Risks Measures Baseline Data Collection Period: PLWD: Data related to demographics, meds, diagnoses, and type of dementia will be collected via chart review. The following assessments will be administered directly to PLWD: the Mini-Mental Status Examination, the Dementia Quality of Life Scale, and the Geriatric Depression Scale-Short Form. In addition, a researcher will ask the PLWD 20 questions to learn about his/her background, interests, and preferences. Researchers will interview LTC facility CPs to implement the Neuropsychiatric Inventory-Nursing Home. FMs A researcher will interview each FM to collect demographics and to implement the Quality of Carer-patient Relationship (QCPR) measure, which measures warmth and/or absence of conflict or critique on a 5-point scale (Sprite et al, 2002). FMs will also be asked to fill out an online form to provide information about their loved one's background, interests, and preferences, etc. If preferred, he/she will be able to provide this information via a phone interview. Info about the PLWD information will be used to automatically recommend activities based upon the person's background, interests, and preferences. FM will also take pre-quizzes related to the BRAIN Training Modules. Staff Members A researcher will interview each staff member to collect demographics. Staff will also take pre-quizzes related to the Training Modules.

During the 4-week baseline data collection period, researchers will observe PLWD's engagement and affect during standard, staff-led activities using the MPES and the EPWDS. To ensure a robust comparison for treatment programming, each participant will be observed at least 12 times with each measure, so that means can be calculated for each type of engagement/affect. Staff members will be trained extensively on both measures prior to the commencement of the study. and interrater reliability of at least 85% will be maintained and audited during the study.

Intervention Period Data Collection Period: During a 3-month intervention period, PLWD will be invited to use the app three times per week. Four Nursing Assistants (NAs)--one for each Experimental site-will implement the intervention as individual activity sessions lasting 20-30 minutes with the PLWD. Most activity sessions will be implemented by the NAs. However, two activity sessions per month for each PLWD be implemented by the PLWD's family members. (Please note: In previous studies the study team has successfully engaged family members to participate in trials and are certain that this level of engagement is feasible in this trial.) In addition, LTC staff members will use the app at least twice during the intervention session (with any PLWD at his/her facility), so that they can provide feedback about the BRAIN platform. Please note: prior to using the BRAIN Platform, the NAs, FMs, and Staff Members will take the BRAIN Training Modules, so that they know how to successfully facilitate activities with PLWD and know how to use the BRAIN Platform itself. During initial activity sessions, the AI will automatically recommend activity content based upon the PLWD's background, interests, and preferences. After this, the AI will also consider the relative success of previously implemented activity sessions.

During each activity session, researchers will observe the PLWD using the MPES and EPWDS. Observations will be conducted via video, since each activity session will be automatically video recorded by the Home App. (Video consent will be obtained from the person responsible for the PLWD's medical decisions.) Session length and time of day will also be noted. Three satisfaction questions will be posed to PLWD at the end of each session: (1) did you enjoy this activity? (2) would you like to do an activity like this again sometime? and (3) would you recommend this activity to others? The same three satisfaction questions will be posed to FMs and LTC Staff Members each time they facilitate a BRAIN activity.

Post-Treatment Data Collection Period: For PLWD, the MMSE, DEMQOL, GDS-SF, and NPI-NH will be implemented again after the Intervention Period is complete. This will allow us to investigate whether any long-term effects are seen. FMs will take post-training quizzes after completing the training modules and fill out the QCPR again. Staff Members will take post-training quizzes.

03

Conditions studied

  • Dementia
  • Alzheimer Disease
  • Vascular Dementia
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 65+ years old
  • Clinical diagnosis of dementia (any type)
  • Able to speak conversational English

Exclusion criteria

Exclusion Criteria:

  • Completely unable to communicate verbally
  • Serious visual or hearing impairments
  • Signs of rapid decline over the last three months (based upon staff report)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Experimental, BRAIN Programming

    PLWD in the Experimental Group will be invited to use the BRAIN intervention twice per week for 3 months. Each session is expected to last 20-30 minutes. The BRAIN app will initially recommend activities for each PLWD based upon his/her background/interests/preferences, which will be collected when the PLWD first enrolls in the study. After the initial sessions, the BRAIN app will use AI to recommend new activities for subsequent sessions. These recommendations will be based upon the AI's rating of the relative success or failure of the activities initially provided to the PLWD.

    Behavioral: The BRAIN App

  • No intervention
    Control: Standard Programming / Care

    PLWD in the Control Group will participate in standard care / programming for 3 months.

Interventions

  • BehavioralThe BRAIN App

    The BRAIN App is digital engagement platform that uses AI to tailor activities to each person's specific interests / background.

06

What researchers measure

Primary outcomes

  1. Menorah Park Engagement Scale (MPES)

    The Menorah Park Engagement Scale measures four types of engagement. Constructive Engagement, Passive Engagement, Other Engagement, and Non-Engagement. It also measures pleasure. Scores on each type of engagement item range from 0 to 2 with higher scores indicating a better outcome for Constructive Engagement, Passive Engagement, and Pleasure. Higher scores represent worse outcomes for Distracted and Non Engagement.

    Time frame: Baseline, that is, Weeks 1 - 4

  2. Menorah Park Engagement Scale (MPES)

    The Menorah Park Engagement Scale measures four types of engagement. Constructive Engagement, Passive Engagement, Other Engagement, and Non-Engagement. It also measures pleasure. Scores on each type of engagement item range from 0 to 2 with higher scores indicating a better outcome for Constructive Engagement, Passive Engagement, and Pleasure. Higher scores represent worse outcomes for Distracted and Non Engagement.

    Time frame: Intervention Period, that is, Weeks 5-16

  3. Engagement for Persons with Dementia Scale (EPWDS)

    This scale measures the engagement in 5 domains: affective, visual, verbal, behavioral and social. Scores range from zero (0) to 36 with higher scores indicating a better outcome.

    Time frame: Baseline, that is, Weeks 1 - 4

  4. Engagement for Persons with Dementia Scale (EPWDS)

    This scale measures the engagement in 5 domains: affective, visual, verbal, behavioral and social. Scores range from zero (0) to 36 with higher scores indicating a better outcome.

    Time frame: Baseline, that is, Weeks 5-16

Secondary outcomes

  1. Dementia Related Quality of Life (DEMQOL)

    The DEMQOL measures quality of life, composed of 28 items. Scores range from zero (0) to 112. Higher scores represent better outcomes.

    Time frame: Baseline, that is, Weeks 1 - 4

  2. Dementia Related Quality of Life (DEMQOL)

    The DEMQOL measures quality of life, composed of 28 items. Scores range from zero (0) to 112. Higher scores represent better outcomes.

    Time frame: Post-Intervention, that is, Weeks 17-18

  3. Neuropsychiatric Inventory--Nursing Home (NPI-NH)

    The NPI-NH measures 12 types of neuropsychiatric symptoms, including their severity and frequency. The total score for F x S ranges from 0 to 120. Lower scores indicate better outcomes.

    Time frame: Baseline, that is, Weeks 1 - 4

  4. Neuropsychiatric Inventory--Nursing Home (NPI-NH)

    The NPI-NH measures 12 types of neuropsychiatric symptoms, including their severity and frequency. The total score for F x S ranges from 0 to 120. Lower scores indicate better outcomes.

    Time frame: Post-Intervention, that is, Weeks 17-18

  5. Quality of Carer-Patient Relationship (QCPR)

    This 14-item scale measures warmth and/or absence of conflict or critique on a 5-point scale Scores range from zero (0) to 56, with higher scores indicating better outcomes.

    Time frame: Baseline, that is, Weeks 1 - 4

  6. Quality of Carer-Patient Relationship (QCPR)

    This 14-item scale measures warmth and/or absence of conflict or critique on a 5-point scale Scores range from zero (0) to 56, with higher scores indicating better outcomes.

    Time frame: Post-Intervention, that is, Weeks 17-18

  7. Mini-Mental Status Examination (MMSE) Mini-Mental Status Examination (MMSE)Mini-Mental Status Examination (MMSE)

    The MMSE measures cognition. The possible scores range from 0 to 30, with high scores indicating a better outcome. A common cutoff for dementia is 23 or lower.

    Time frame: Baseline, that is, Weeks 1 - 4

  8. Mini-Mental Status Examination (MMSE) Mini-Mental Status Examination (MMSE)Mini-Mental Status Examination (MMSE)

    The MMSE measures cognition. The possible scores range from 0 to 30, with high scores indicating a better outcome. A common cutoff for dementia is 23 or lower.

    Time frame: Post-Intervention, that is, Weeks 17-18

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — This is TBD.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Nov 2026, 18 months after the start.

Of 46 industry-sponsored interventional studies with no phase under Dementia, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 35. This study's planned 18 months is close to that.

Counting every sponsor, half of 908 studies reached it within 25 months; a quarter within 11 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2024
First posted
Mar 7, 2024
StartActual
May 15, 2025
Primary completionEst.
Nov 30, 2026
CompletionEst.
Nov 30, 2026
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06298474
Lead sponsor
Hopeful Aging
Responsible party
Sponsor
First posted
Mar 7, 2024
Start date
May 15, 2025
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Sep 15, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion